The CENSER trial tested whether starting low-dose norepinephrine early during resuscitation could improve shock control in adults with sepsis and hypotension. In this randomised, placebo-controlled study, the early norepinephrine group received vasopressor support substantially sooner than the standard-care group. The primary endpoint—shock control by 6 hours—was significantly more frequent with early norepinephrine. The intervention was also associated with lower rates of cardiogenic pulmonary oedema and new-onset arrhythmia in the study population. However, the trial was a phase II single-centre study and was not powered to establish a mortality benefit; 28-day mortality did not differ significantly between groups. The findings support an important physiologic principle: persistent vasodilation and hypotension should not necessarily be allowed to continue while clinicians administer increasingly large volumes of intravenous fluid. Early vasopressor support may help restore perfusion pressure while limiting fluid-related complications in selected patients. At the same time, the results should not be interpreted as proof that every patient with septic hypotension needs immediate vasopressors before appropriate fluid assessment. The study is best viewed as evidence that timing matters and that modern sepsis resuscitation should balance circulation, fluid tolerance and individual patient physiology.